NCT05574296View on ClinicalTrials.gov

Hydrogen's Feasibility and Safety as a Therapy in ECPR

PHASE1RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

August 31, 2027

Conditions
Cardiac ArrestExtracorporeal Membrane OxygenationReperfusion Injury
Interventions
DRUG

Hydrogen

Hydrogen gas (2%) in air or oxygen administered for 72 hours via ventilator and ECMO membrane. Oxygen concentration titrated per clinical team.

OTHER

Usual care

Usual care post-ECPR event, including targeted temperature management.

Trial Locations (4)

20010

NOT_YET_RECRUITING

Children's National Hospital, Washington D.C.

64108

NOT_YET_RECRUITING

Children's Mercy Kansas City, Kansas City

84132

NOT_YET_RECRUITING

Primary Children's Hospital, Salt Lake City

02115

RECRUITING

Boston Children's Hospital, Boston

All Listed Sponsors
lead

Boston Children's Hospital

OTHER